

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

---

**FORM 6-K**

---

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16  
of the Securities Exchange Act of 1934**

Date of Report: October 22, 2024

Commission File Number: 001-39307

---

**Legend Biotech Corporation**

(Exact Name of Registrant as Specified in its Charter)

---

**2101 Cottontail Lane  
Somerset, New Jersey 08873  
(Address of principal executive office)**

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K on paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K on paper as permitted by Regulation S-T Rule 101(b)(7):

---

---

On October 22, 2024, due to the loss of power to cast the majority of votes at the 2024 Annual General Meeting of Shareholders of Legend Biotech Corporation (the "Company"), Genscript Biotech Corporation announced that they have resolved to deconsolidate the financial statements of the Company and its subsidiaries, in accordance with the requirements of the Hong Kong Financial Reporting Standards.

This report on Form 6-K shall be deemed to be incorporated by reference in the registration statements of the Company on Form F-3 (Nos. 333-257625, 333-272222 and 333-278050) and Form S-8 (No. 333-239478), to the extent not superseded by documents or reports subsequently filed.

---

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

#### LEGEND BIOTECH CORPORATION

Date: October 22, 2024

By: /s/ Ying Huang  
Name: Ying Huang, Ph.D.  
Title: Chief Executive Officer